Form 4: OCUL CSO Sells Shares for Tax Obligations

Ocular Therapeutix Chief Scientific Officer Jeffrey S. Heier sold 10,502 shares of common stock at a weighted average price of $11.04 to cover tax withholding obligations related to restricted stock unit vesting.

Summary

• Jeffrey S. Heier, Chief Scientific Officer of Ocular Therapeutix, Inc. (OCUL), sold 10,502 shares of the company's common stock.
• The transaction occurred on October 2, 2025, at a weighted average price of $11.04 per share, with individual sales ranging from $10.99 to $11.0866.
• The sale was executed pursuant to a durable automatic sale instruction adopted by Mr. Heier on April 9, 2024, under a Rule 10b5-1(c) plan.
• The primary purpose of the sale was to satisfy tax withholding obligations in connection with the vesting of restricted stock units (RSUs) on October 1, 2025.
• This transaction was a non-discretionary trade by the reporting person.
• Following the sale, Mr. Heier beneficially owns 249,409 shares of Ocular Therapeutix common stock.

Sentiment

Score: 5

Explanation: The transaction is a routine, non-discretionary sale to cover tax obligations related to RSU vesting, indicating no change in sentiment regarding the company's prospects or any new material information.

Positives

• The sale was non-discretionary, executed under a pre-arranged Rule 10b5-1 plan, indicating it was not based on new insider information or a change in executive sentiment.
• The underlying event, the vesting of restricted stock units, represents a positive compensation event for the Chief Scientific Officer.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Management Comments

• The sales do not represent a discretionary trade by the reporting person.

Industry Context

This Form 4 filing details an individual insider transaction, which is specific to Ocular Therapeutix and its Chief Scientific Officer, and does not provide information relevant to broader industry trends or competitive landscape analysis.

Stakeholder Impact

• Shareholders: The impact on shareholders is minimal as the sale is non-discretionary and for tax purposes, not indicative of a change in executive confidence or a strategic shift by the company.

Key Dates

Recommendation

The filing details a routine, non-discretionary sale by a Chief Scientific Officer to cover tax obligations from RSU vesting. This type of transaction does not reflect a change in the executive's confidence in the company's future and therefore provides no new information to alter an existing investment thesis. A 'hold' recommendation is appropriate as there are no fundamental changes indicated by this filing.

Keywords

OCULAR THERAPEUTIX, OCUL, Form 4, Insider Transaction, Stock Sale, Jeffrey S. Heier, Chief Scientific Officer, RSU Vesting, Tax Withholding, 10b5-1 Plan